Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study

[1]  L. Peterson,et al.  Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Berger,et al.  Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia. , 2002, Clinical lymphoma.

[3]  M. Berger,et al.  Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody‐Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse , 2001, Journal of clinical pharmacology.

[4]  M. Berger,et al.  Impact of Age and Gender on the Pharmacokinetics of Gemtuzumab Ozogamicin , 2001, Pharmacotherapy.

[5]  I. Bernstein,et al.  Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  X. H. Chen,et al.  Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  I. Bernstein,et al.  Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. , 2001, Blood.

[8]  I. Bernstein,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate , 2017 .

[9]  R. Nilakantan,et al.  Calicheamicin gamma 1I and DNA: molecular recognition process responsible for site-specificity. , 1989, Science.

[10]  F. Lo Coco,et al.  Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin. , 2006, Clinical advances in hematology & oncology : H&O.

[11]  Irwin Hollander,et al.  Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. , 2002, Bioconjugate chemistry.

[12]  I. Bernstein,et al.  Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. , 1992, Cancer research.